NZ704819A - Dry powder vancomycin compositions and associated methods - Google Patents
Dry powder vancomycin compositions and associated methodsInfo
- Publication number
- NZ704819A NZ704819A NZ704819A NZ70481912A NZ704819A NZ 704819 A NZ704819 A NZ 704819A NZ 704819 A NZ704819 A NZ 704819A NZ 70481912 A NZ70481912 A NZ 70481912A NZ 704819 A NZ704819 A NZ 704819A
- Authority
- NZ
- New Zealand
- Prior art keywords
- dry powder
- vancomycin
- pharmaceutically acceptable
- acceptable salt
- associated methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 10
- 238000000034 method Methods 0.000 title claims abstract 8
- 108010059993 Vancomycin Proteins 0.000 title claims abstract 7
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 title claims abstract 7
- 229960003165 vancomycin Drugs 0.000 title claims abstract 7
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 title claims abstract 7
- 239000000843 powder Substances 0.000 title claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 150000001413 amino acids Chemical class 0.000 claims abstract 2
- 230000002209 hydrophobic effect Effects 0.000 claims abstract 2
- 238000001694 spray drying Methods 0.000 claims abstract 2
- 239000007787 solid Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present disclosure provides a method comprising spray drying an aqueous composition comprising vancomycin or a pharmaceutically acceptable salt thereof and a hydrophobic amino acid so as to form a dry powder composition.
Claims (6)
1. A method comprising spray drying an aqueous composition comprising vancomycin, or a pharmaceutically acceptable salt thereof, and a hydrophobic amino acid so as to form a dry powder composition.
2. The method of claim 1, wherein the dry powder composition is substantially amorphous.
3. The method of claim 1, wherein the aqueous composition comprising vancomycin or a pharmaceutically acceptable salt thereof has a solids content of at least 1% by weight water.
4. The method of claim 1, wherein the aqueous composition comprising vancomycin or a pharmaceutically acceptable salt thereof has a solids content of at least 2% by weight water.
5. The method of claim 1, wherein the aqueous composition comprising vancomycin or a pharmaceutically acceptable salt thereof has a solids content of at least 4% by weight water.
6. A dry powder composition comprising vancomycin or a pharmaceutically acceptable salt thereof, prepared by a method of claim 1. SAVARA, INC. By the Attorneys for the Applicant SPRUSON & FERGUSON Per: AH25(9683874_1):GGG
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487971P | 2011-05-19 | 2011-05-19 | |
| US61/487,971 | 2011-05-19 | ||
| NZ618002A NZ618002B2 (en) | 2011-05-19 | 2012-05-21 | Dry powder vancomycin compositions and associated methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ704819A true NZ704819A (en) | 2016-05-27 |
| NZ704819B2 NZ704819B2 (en) | 2016-08-30 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| CA2836643C (en) | 2017-11-14 |
| WO2012159103A1 (en) | 2012-11-22 |
| EP2709646A1 (en) | 2014-03-26 |
| EP2709646A4 (en) | 2015-05-13 |
| CN103717231A (en) | 2014-04-09 |
| KR20140032450A (en) | 2014-03-14 |
| KR101763195B1 (en) | 2017-07-31 |
| CA2836643A1 (en) | 2012-11-22 |
| MX2013013503A (en) | 2014-05-12 |
| SG195038A1 (en) | 2013-12-30 |
| CN103717231B (en) | 2016-08-17 |
| BR112013029803B1 (en) | 2021-07-13 |
| JP2014515356A (en) | 2014-06-30 |
| CA2981038C (en) | 2018-09-25 |
| JP6012716B2 (en) | 2016-10-25 |
| IL229506B (en) | 2019-07-31 |
| MX346244B (en) | 2017-03-13 |
| NZ618002A (en) | 2015-03-27 |
| CA2981038A1 (en) | 2012-11-22 |
| IL229506A0 (en) | 2014-01-30 |
| BR112013029803A2 (en) | 2017-01-17 |
| AU2012254999B2 (en) | 2016-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA110194C2 (en) | Seed coating composition | |
| AU2018236805B2 (en) | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | |
| GB201216469D0 (en) | Stabilisation of viral particles | |
| UA105229C2 (en) | Pharmaceutical formulation | |
| WO2012083122A8 (en) | Inhibitors of influenza viruses replication | |
| NZ600191A (en) | Method for reducing temperature stress of plants | |
| WO2011146583A3 (en) | Nanoparticulate cinacalcet formulations | |
| MY161682A (en) | Storage-stable 2-hydroxy-4- (methylthio) butyronitrile | |
| MY188458A (en) | Formulations for animal feed comprising butyrate salt | |
| UA97391C2 (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| PH12016501175B1 (en) | Formulations of deoxycholic acid and salts thereof | |
| PH12014502493A1 (en) | Novel highly bioavailable, water soluble and sustained release nanoformulations of hydrophobic plant derived compounds and extracts | |
| WO2012052536A3 (en) | Cosmetic composition comprising aloe vera and an isethionic acid derivative | |
| NZ600891A (en) | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs | |
| CA2899024C (en) | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid | |
| MX342842B (en) | Compositions having increased concentrations of carboxymethylcellulose. | |
| MX339840B (en) | Modulators of 5-ht receptors and methods of use thereof. | |
| MX2011012479A (en) | Modulators of 5-ht receptors and methods of use thereof. | |
| WO2017103600A8 (en) | Preparation of respirable zafirlukast particles | |
| WO2011080254A3 (en) | Fungicide hydroximoyl-heterocycles derivatives | |
| WO2013080140A3 (en) | Sunscreen compositions containing a novel preservative system | |
| WO2011139256A3 (en) | Stable rosuvastatin formulations | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| TW201129386A (en) | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients | |
| UA109460C2 (en) | N-hetarylmethyl pyrazolylcarboxamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 MAY 2019 BY SPRUSON + FERGUSON Effective date: 20160930 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2020 BY SPRUSON + FERGUSON Effective date: 20190301 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2021 BY SPRUSON + FERGUSON PTY LTD Effective date: 20200221 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2022 BY CPA GLOBAL Effective date: 20210408 |
|
| LAPS | Patent lapsed |